Somewhat Favorable News Coverage Somewhat Unlikely to Affect Intec Pharma (NTEC) Stock Price

Media headlines about Intec Pharma (NASDAQ:NTEC) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intec Pharma earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.4995590973187 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

NTEC has been the topic of a number of recent research reports. Roth Capital set a $10.00 price objective on Intec Pharma and gave the stock a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $15.00 price objective on Intec Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. Zacks Investment Research raised Intec Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, CIBC reaffirmed an “outperform” rating and set a $15.00 target price (up from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $12.25.

Shares of Intec Pharma (NASDAQ NTEC) opened at $7.20 on Tuesday. Intec Pharma has a 52-week low of $4.20 and a 52-week high of $9.80.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://stocknewstimes.com/2017/11/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-intec-pharma-ntec-stock-price.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply